WHC is still in active development. Read this to understand our approach.
depiction of SHXWCVYOXRDMCX-UHFFFAOYSA-N.svg
tripsit

mdma

Verificar en tripsit

psychonaut

MDMA

Verificar en psychonaut

isomerdesign

MDMA

Verificar en isomerdesign

isomerdesign

(2S)-1-(2H-1,3-Benzo...

Verificar en isomerdesign

isomerdesign

(2R)-1-(2H-1,3-Benzo...

Verificar en isomerdesign

pubchem

3,4-Methylenedioxyme...

Verificar en pubchem

druglab

MDMA

Verificar en druglab

drugmap

Methylenedioxymetham...

Verificar en drugmap

wiki

MDMA

Verificar en wiki

Data

InChI: InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3

Sinónimos: EA-1475,C07577,(RS)-1-(BENZO(D)(1,3)DIOXOL-5-YL)-N-METHYLPROPAN-2-AMINE,mandy,N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE,Phenethylamine, N,alpha-dimethyl-3,4-methylenedioxy-,(2R)-1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine,3,4-Methylenedioxy-N,alpha-dimethyl-beta-phenylethylamine,3,4-methylenedioxymetamphetamine,N-Methyl-3,4-methylenedioxyamphetamine,D11172,md,CHEMBL43048,AKOS006283463,(+-)-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, (+-)-(3,4-Methylenedioxy)methamphetamine,rac-3,4-Methylenedioxymethamphetamine,Methylenedioxymethamfetamine, (RS)-3,4-(methylenedioxy)methamphetamine,KBio1_000962,MIDOMAFETAMINE [INN],NCGC00168266-01,[1-(1,3-Benzodioxol-5-yl)propan-2-yl](methyl)azan,molly,DTXSID90860791,XTC [Street Name],1-(1,3-Benzodioxol-5-yl)-N-methyl-2-propanamine, Midomafetamine,Mandy [Street Name], N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE,Methylenedioxymethamphetamine,(+/-)-3,4-METHYLENEDIOXYMETHAMPHETAMINE,xtc,Ecstasy, DEA No 7405,XTC,3,4-Methylenedioxymethamphetamine,Midomafetamine [USAN],ecstasy,Q69488,Epitope ID:178091, 42542-10-9,MDMA (unspecified),CCRIS 9277,(+/-)-MDMA solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,MDMA (Ecstasy),3,4-Methylenedioxy-N-methylamphetamine (MDMA),(2S)-1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine,(2R)-1-(2H-1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine,Midomafetamine, Methylenedioxymethamphetamine,MDMA,NCGC00168266-02,(+/-)-N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-AMINOPROPANE,N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE [HSDB],54946-52-0,PDSP1_001522,(RS)-3,4-(methylenedioxy)methamphetamine,Methylenedioxy Methamphetamine,Molly,3,4-Methylenedioxy-N-methylamphetamine,UNII-KE1SEN21RM, CHEBI:1391,(+/-)-N,.ALPHA.-DIMETHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE,BDBM50010588,(+/-)-(3,4-Methylenedioxy)methamphetamine,MANDY,[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl](methyl)amine,rac-MDMA (rac-3,4-Methylenedioxymethamphetamine) 1.0 mg/ml in Methanol,METHYLENEDIOXYMETHAMFETAMINE [MART.],Methylenedioxymetamphetamine, MDMA (unspecified),MDM,1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine,(+-)-N-Methyl-3,4-(methylenedioxy)amphetamine,D,L-3,4-METHYLENEDIOXYMETHAMPHETAMINE,X,1,3-Benzodioxole-5-ethanamine, N,.alpha.-dimethyl-,42542-10-9,PHENETHYLAMINE, N,.ALPHA.-DIMETHYL-3,4-METHYLENEDIOXY-,3,4-MDMA,3,4-methylenedioxymethamphetamine,MDMA [MI],Midomafetamine [WHO-DD], 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-,GTPL4574,DivK1c_000962,(2S)-1-(2H-1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine,DL-(3,4-Methylenedioxy)methamphetamine, (+-)-N-Methyl-3,4-(methylenedioxy)amphetamine,SCHEMBL44210, DL-(3,4-Methylenedioxy)methamphetamine,x, 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine,(+-)-(3,4-Methylenedioxy)methamphetamine,NINDS_000962,CHEBI:1391,KE1SEN21RM,ADAM, MDMA,METHYLENEDIOXYMETHAMPHETAMINE [WHO-DD], HSDB 6929,adam,N,alpha-Dimethyl-1,3-benzodioxole-5-ethanamine,3,4-methylenedioxy-n-methylamphetamine,3,4-methylenedioxymethylamphetamine, Ecstasy,Midomafetamine (USAN/INN),DEA No. 7405,DB01454,HSDB 6929, N,alpha-Dimethyl-1,3-benzodioxole-5-ethanamine,(+/-)-N-Methyl-3,4-(methylenedioxy)amphetamine,PDSP2_001506,1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-, 3,4-methylenedioxymethamphetamine,IDI1_000962

Estimated data

Solubilidad: -1.425 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 93.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.